Navigation Links
Hospira to Host Conference Call for First-Quarter 2009 Results
Date:3/30/2009

LAKE FOREST, Ill., March 30 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today announced that it will host a conference call to discuss its first-quarter 2009 results on Tuesday, April 28, 2009, at 8 a.m. Central time.

The company will release its first-quarter 2009 results earlier that morning, before the U.S. stock market open and the conference call.

A live webcast of the conference call will be available on Hospira's Web site at www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper computer setup to receive the webcast. A replay will be available on the Hospira Web site for 30 days following the call.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Hospira to Present at Cowen and Companys 29th Annual Health Care Conference March 17
2. Hospira Expands Board of Directors
3. Hospira Reports Fourth-Quarter and Full-Year 2008 Results
4. Hospiras Precedex(R) Phase IV Study Published in the Journal of the American Medical Association
5. Hospira to Host Conference Call for Fourth-Quarter 2008 Results and 2009 Projections
6. Hospira to Present at J.P. Morgans 27th Annual Healthcare Conference January 14
7. Hospira Names Ken Meyers to Lead Human Resources
8. Hospira Reports Third-Quarter 2008 Results
9. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
10. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection
11. Hospira Announces New Contracts With Premier Purchasing Partners for Infusion Devices, Solutions And Equipment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Park Systems , a leader in Atomic ... SEMICONWest attendees and Park customers on July 11, 2017 from 12-2pm at the ... Chairman & CEO of Park Systems, and Prof. Krishna Saraswat , Rickey/Nielsen Professor ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, ... regions access to insurance assistance and financial planning services, is announcing the commencement ... families in the region facing financial crisis. , Matthew 25: Ministries (M25M) is ...
(Date:6/27/2017)... ... 2017 , ... Excel Medical, the leader in Next-Generation Medical ... Executive Vice President, Sales and Marketing. Finnegan is a widely known industry leader ... leadership. He has received industry recognition for innovations and new approaches to sales ...
(Date:6/27/2017)... , ... June 27, 2017 , ... Harbour , ... token assets on the Ethereum blockchain, has released their technical specifications . , ... there has been little systematic approach for determining which offerings will garner the greatest ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Association’s SUNucate efforts, Louisiana became the sixth state to pass legislation which ... Governor John Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, ...
Breaking Medicine News(10 mins):
(Date:6/13/2017)... Ind. , June 13, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that the U.S. Food and Drug ... dated June 3, 2015 relating to its Zhejiang, ... "The successful clearance of the ... manufacturing facility is a measure of the progress ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
(Date:6/9/2017)... 9, 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders ... design, manufacture, sale and distribution of the AeroForm® Tissue ... of its commercial roll-out in the United ... than one hundred (100) medical institutions and health systems, ... a needle-free alternative for women who choose reconstructive surgery ...
Breaking Medicine Technology: